Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,403,956
  • Shares Outstanding, K 115,970
  • Annual Sales, $ 219,750 K
  • Annual Income, $ -886,120 K
  • 60-Month Beta 1.50
  • Price/Sales 74.22
  • Price/Cash Flow N/A
  • Price/Book 11.59
Trade ALNY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -1.75
  • Number of Estimates 9
  • High Estimate -1.59
  • Low Estimate -1.96
  • Prior Year -1.92
  • Growth Rate Est. (year over year) +8.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
129.11 +5.71%
on 09/22/20
148.76 -8.25%
on 10/01/20
+5.56 (+4.25%)
since 09/21/20
3-Month
119.67 +14.05%
on 09/04/20
161.48 -15.48%
on 07/23/20
-21.55 (-13.64%)
since 07/21/20
52-Week
83.06 +64.31%
on 10/31/19
167.33 -18.44%
on 07/20/20
+49.72 (+57.31%)
since 10/21/19

Most Recent Stories

More News
Alnylam (ALNY) Gets Positive CHMP Opinion for Lumasiran

Alnylam (ALNY) gets positive opinion from the CHMP for lumasiran for the treatment of primary hyperoxaluria type 1.

REGN : 572.40 (-0.73%)
ALNY : 136.48 (-3.51%)
NVS : 84.14 (-1.81%)
EBS : 93.04 (-3.79%)
Alnylam Receives Positive CHMP Opinion for OXLUMO(TM) (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups

--- European Commission Decision on Approval Expected in Q4 2020 -

ALNY : 136.48 (-3.51%)
Vir and Alnylam to Webcast Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus Mini-Conference

Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that Phil Pang, M.D., Ph.D., Chief Medical Officer of Vir, and Vasant Jadhav, Ph.D., Vice President,...

VIR : 34.57 (-2.51%)
ALNY : 136.48 (-3.51%)
Alnylam Releases Positive Top-Line Rare Disease Lumasiran Data

Alnylam (ALNY) releases positive top-line data from the ILLUMINATE-B pediatric phase III study of lumasiran, in development for the treatment of PH1.

REGN : 572.40 (-0.73%)
SNY : 49.17 (-1.42%)
ALNY : 136.48 (-3.51%)
NVS : 84.14 (-1.81%)
Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six

--- Lumasiran Demonstrated Clinically Significant Reduction in Urinary Oxalate Levels Relative to Baseline in Children as Young as Four Months Old -

ALNY : 136.48 (-3.51%)
Alnylam to Webcast Presentation at Chardan Virtual 4th Annual Genetic Medicines Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Virtual 4th Annual Genetic Medicines...

ALNY : 136.48 (-3.51%)
Alexion & Caelum Begin Studies on CAEL-101 in AL Amyloidosis

Alexion (ALXN) and partner Caelum Biosciences begin phase III studies on CAEL-101 in AL amyloidosis.

ALXN : 118.19 (-4.69%)
ALNY : 136.48 (-3.51%)
IONS : 46.36 (-2.19%)
AKCA : 18.17 (+0.17%)
Why Is Alnylam (ALNY) Down 14.8% Since Last Earnings Report?

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALNY : 136.48 (-3.51%)
Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable

--- New Clinical Data Presented at the European Society of Cardiology 2020 Congress Provide Further Evidence that Treatment with Patisiran may Lead to Substantial Reduction in Cardiac Amyloid Burden in...

ALNY : 136.48 (-3.51%)
Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:

MS : 50.38 (-2.12%)
ALNY : 136.48 (-3.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies,...

See More

Key Turning Points

2nd Resistance Point 146.09
1st Resistance Point 141.28
Last Price 136.48
1st Support Level 133.80
2nd Support Level 131.13

See More

52-Week High 167.33
Last Price 136.48
Fibonacci 61.8% 135.14
Fibonacci 50% 125.19
Fibonacci 38.2% 115.25
52-Week Low 83.06

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar